Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones

Int J Antimicrob Agents. 2005 Oct;26(4):323-6. doi: 10.1016/j.ijantimicag.2005.06.017.


In a database cohort study, the risk of adverse birth outcome in Danish women who redeemed a fluoroquinolone prescription during pregnancy was examined. Among 87 women who redeemed a fluoroquinolone prescription at any time during the pregnancy, the prevalence ratio of preterm birth was 1.4 (95% confidence interval (CI), 0.6-3.2), one woman had a stillbirth, and no children died during the perinatal period. Among 130 women who redeemed a prescription during the first trimester or 30 days before conception, the prevalence ratio of congenital malformation was 0.7 (95% CI, 0.3-2.0) and the prevalence ratio of bone malformations was 2.2 (95% CI, 0.7-6.7). Our study raises the concern that prenatal fluoroquinolone exposure may be associated with an increased risk of bone malformations.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormalities, Drug-Induced / epidemiology*
  • Adult
  • Bone and Bones / abnormalities*
  • Cohort Studies
  • Databases, Factual
  • Denmark / epidemiology
  • Female
  • Fluoroquinolones / administration & dosage
  • Fluoroquinolones / adverse effects*
  • Humans
  • Infant, Newborn
  • Population
  • Pregnancy
  • Pregnancy Complications / chemically induced
  • Pregnancy Complications / epidemiology*
  • Pregnancy Outcome*
  • Pregnancy Trimesters
  • Premature Birth / epidemiology
  • Prevalence


  • Fluoroquinolones